Today, the CEO of Madrigal Pharmaceuticals Inc (MDGL), Paul A. Friedman, bought shares of MDGL for $496K.
Following this transaction Paul A. Friedman’s holding in the company was increased by 2.61% to a total of $18.93 million. In addition to Paul A. Friedman, 2 other MDGL executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Currently, Madrigal Pharmaceuticals Inc has an average volume of 763.6K.
Based on 8 analyst ratings, the analyst consensus is Strong Buy with an average price target of $286.33, reflecting a 137.6% upside. Seven different firms, including Citigroup and Oppenheimer, currently also have a Buy rating on the stock.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia.
